Edition:
India

Kyowa Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,606JPY
23 Oct 2020
Change (% chg)

¥-19 (-0.72%)
Prev Close
¥2,625
Open
¥2,646
Day's High
¥2,652
Day's Low
¥2,606
Volume
471,000
Avg. Vol
733,380
52-wk High
¥3,060
52-wk Low
¥1,849

Select another date:

Thu, Jul 9 2020

BRIEF-Mylan And Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval Of Hulio (Adalimumab-Fkjp)

* MYLAN AND FUJIFILM KYOWA KIRIN BIOLOGICS ANNOUNCE U.S. FDA APPROVAL OF HULIO® (ADALIMUMAB-FKJP)

BRIEF-Ultragenyx And Kyowa Kirin Announce U.S. FDA Approval Of Crysvita(Reg) (Burosumab) For The Treatment Of Tumor-Induced Osteomalacia (TIO)

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE U.S. FDA APPROVAL OF CRYSVITA(REG) (BUROSUMAB) FOR THE TREATMENT OF TUMOR-INDUCED OSTEOMALACIA (TIO) Source text - https://bit.ly/2UXTP2H Further company coverage:

BRIEF-Kyowa Kirin Says Presented Impact Of Baseline Dyskinesia On Safety And Efficacy Of Nourianz In Patients With Parkinson's Disease

* KYOWA KIRIN CO LTD - IMPACT OF BASELINE DYSKINESIA ON SAFETY AND EFFICACY OF NOURIANZ IN PATIENTS WITH PARKINSON'S DISEASE PRESENTED

BRIEF-Mei Pharma And Kyowa Kirin Announce Updated Clinical Data From Early-Stage Follicular Lymphoma Study

* MEI PHARMA AND KYOWA KIRIN ANNOUNCE UPDATED CLINICAL DATA FROM THE PHASE 1B STUDY EVALUATING ME-401 ON AN INTERMITTENT SCHEDULE IN PATIENTS WITH FOLLICULAR LYMPHOMA AND OTHER B-CELL MALIGNANCIES; DATA TO BE FEATURED IN THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2020 VIRTUAL SCIENTIFIC PROGRAM

Select another date: